These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

320 related items for PubMed ID: 20535957

  • 1. [mTOR inhibitors].
    Oya M.
    Nihon Rinsho; 2010 Jun; 68(6):1067-71. PubMed ID: 20535957
    [Abstract] [Full Text] [Related]

  • 2. Temsirolimus in patients with advanced renal cell carcinoma: an overview.
    Bhatia S, Thompson JA.
    Adv Ther; 2009 Jan; 26(1):55-67. PubMed ID: 19172239
    [Abstract] [Full Text] [Related]

  • 3. [mTOR inhibitors: temsirolimus and everolimus in the treatment of renal cell carcinoma].
    Ravaud A, Bernhard JC, Gross-Goupil M, Digue L, Ferriere JM.
    Bull Cancer; 2010 Jan; 97():45-51. PubMed ID: 20418203
    [Abstract] [Full Text] [Related]

  • 4. Management of mTOR inhibitor side effects.
    Creel PA.
    Clin J Oncol Nurs; 2009 Dec; 13 Suppl():19-23. PubMed ID: 19948456
    [Abstract] [Full Text] [Related]

  • 5. Morphoproteomic and molecular concomitants of an overexpressed and activated mTOR pathway in renal cell carcinomas.
    Lin F, Zhang PL, Yang XJ, Prichard JW, Lun M, Brown RE.
    Ann Clin Lab Sci; 2006 Dec; 36(3):283-93. PubMed ID: 16951269
    [Abstract] [Full Text] [Related]

  • 6. mTOR pathway inhibition in renal cell carcinoma.
    Pinto Marín A, Redondo Sánchez A, Espinosa Arranz E, Zamora Auñón P, Castelo Fernández B, González Barón M.
    Urol Oncol; 2012 Dec; 30(4):356-61. PubMed ID: 20207176
    [Abstract] [Full Text] [Related]

  • 7. Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.
    Chan HY, Grossman AB, Bukowski RM.
    Adv Ther; 2010 Aug; 27(8):495-511. PubMed ID: 20623346
    [Abstract] [Full Text] [Related]

  • 8. Vascular endothelial growth factor and mTOR pathways in renal cell carcinoma: differences and synergies of two targeted mechanisms.
    Mulders P.
    BJU Int; 2009 Dec; 104(11):1585-9. PubMed ID: 20053190
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Clinical trial experience with temsirolimus in patients with advanced renal cell carcinoma.
    Hudes GR, Berkenblit A, Feingold J, Atkins MB, Rini BI, Dutcher J.
    Semin Oncol; 2009 Dec; 36 Suppl 3():S26-36. PubMed ID: 19963097
    [Abstract] [Full Text] [Related]

  • 11. Mechanisms of Disease: survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCC.
    Figlin RA.
    Nat Clin Pract Oncol; 2008 Oct; 5(10):601-9. PubMed ID: 18607393
    [Abstract] [Full Text] [Related]

  • 12. Eosinophilic rash secondary to temsirolimus.
    Gandhi M, Kuzel T, Lacouture M.
    Clin Genitourin Cancer; 2009 Aug; 7(2):E34-6. PubMed ID: 19692320
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Mammalian target of rapamycin, its mode of action and clinical response in metastatic clear cell carcinoma].
    Shuuin T, Karashima H.
    Gan To Kagaku Ryoho; 2009 Jul; 36(7):1076-9. PubMed ID: 19620795
    [Abstract] [Full Text] [Related]

  • 17. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.
    Albert S, Serova M, Dreyer C, Sablin MP, Faivre S, Raymond E.
    Expert Opin Investig Drugs; 2010 Aug; 19(8):919-30. PubMed ID: 20569080
    [Abstract] [Full Text] [Related]

  • 18. Temsirolimus in renal cell carcinoma.
    Otto T, Eimer C, Gerullis H.
    Transplant Proc; 2008 Dec; 40(10 Suppl):S36-9. PubMed ID: 19100905
    [Abstract] [Full Text] [Related]

  • 19. mTOR in renal cell cancer: modulator of tumor biology and therapeutic target.
    Wysocki PJ.
    Expert Rev Mol Diagn; 2009 Apr; 9(3):231-41. PubMed ID: 19379082
    [Abstract] [Full Text] [Related]

  • 20. [Use of mTOR-inhibitors in solid tumors].
    Seidel C, Grünwald V.
    Med Monatsschr Pharm; 2011 Apr; 34(4):116-26; quiz 127-8. PubMed ID: 21528529
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.